Researchers can now order their mutation of choice in bit.bio’s opti-ox TM powered human-iPSC derived cells, receiving consistent, defined, cryopreserved products that can be immediately incorporated ...

CAMBRIDGE, England--(BUSINESS WIRE)--bit.bio, the company coding human cells for novel cures, today launches its first set of muscle cell disease model products designed to advance the discovery and ...

Immorta Bio Inc. has reported new data demonstrating that its combination therapy of Senovax, a first-in-class senolytic immunotherapy, and personalized mesenchymal stem cells (pMSCs) from its ...

The PharmTech Group spoke with BIOVECTRA's director of Business Development, Nucleic Acid Modalities, Jessica Madigan, about the concept of flexibility in outsourcing and the 2024 BIO Convention.

Accurate cancer models are integral to the success of preclinical research yet have proven elusive. Mindy Goldsborough (ATCC, VA, USA) discusses the ongoing efforts to develop improved in vitro models ...

Stem cells hold immense potential in research and therapeutic development. One area where they are being utilized is in the development of advanced cell models, such as organoids. Stem cell-derived ...